Lynch syndrome (LS) patients are at markedly increased risk for colorectal cancer. It is being increasingly recognized that the immune system plays an essential role in LS tumor development. Therefore, immune interception strategies are emerging as a novel way to prevent cancer in LS. This phase Ib, placebo-controlled, randomized clinical trial and a co-clinical trial using a LS mouse model and patient-derived organoids aims to evaluate the safety and tolerability as well as to discover novel molecular pathways involved in the activity of Naproxen as chemoprevention in LS patients. SOURCE: Eduardo Vilar (EVilar@mdanderson.org) -  The University of Texas MD Anderson Cancer Center

Pluto Bioinformatics

GSE144381 (human): Naproxen Chemoprevention Promotes Immune Activation In Lynch Syndrome Colorectal Mucosa